Skip to main content

Table 2 Summary characteristics of studies with 100% efficacy of artemisinin combination therapy at day 28 among P. falciparum patients

From: Efficacy and safety of artemisinin-based combination therapies for the treatment of uncomplicated malaria in pediatrics: a systematic review and meta-analysis

Author, publication year Country Setting Drug Age n N p
Davlantes 2018 [25] Angola Benguela (stable mesoendemic transmission) DP < 12 years 85 85 100
ASAQ < 12 years 90 90 100
LundaSul-hyperendemic transmission) DP < 5 years 89 89 100
Ojurongbe 2013 [34] Nigeria University hospital, transmission throughout the year AL 6 m to 12 years 89 89 100
ASAQ   71 71 100
Plucinski 2017 [35] Angola Benguela (stable mesoendemic transmission) ASAQ 6 m to 12 years 66 66 100
LundaSul-hyperendemic transmission) DP   76 76 100
ASAQ   56 56 100
Ramharter 2008 [37] Gabon Hospital. transmitted perennially AP (tablet) 2–14 years 13 13 100
AP (Granule) 2–14 years 14 14 100
Sawa 2013 [38] Kenya moderate transmission intensity DP 6 m to 10 years 137 137 100
Shayo 2014 [39] Tanzania Health Center. Moderate to high transmission DP 6 months to 10 years 40 40 100
  AL 6 m to 10 years 21 21 100
Mens 2008 [31] Kenya primary health centers, transmission low and predominantly seasonal DP 6 m to 12 years 67 67 100
AL 6 m to 12 years 66 66 100
Kabanywanyi 2007 [28] Tanzania health facilities, perennial with seasonal peaks AL 6 to 59 months 86 86 100
Dorkenoo 2012 [27] Togo Urban, university and childs hospital, endemic or seasonal transmission AL 6 to 59 months 538 538 100
\